Pozen, Inc. and AstraZeneca began the Phase III program for PN 400, a fixed dose combination of the proton pump inhibitor (PPI), esomeprazole magnesium, with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet. An NDA is targeted for 1H2009. The two companies have also amended terms of their August 2006 collaboration and license agreement. Under the terms of the amended agreement, AZ will pay Pozen as much as $345 million for the achievement of development, regulat...